Clinical Results of Asqelio Trifocal Toric Diffractive Intraocular Lens
Sponsored by AST Products, Inc.
About this trial
Last updated a year ago
Study ID
Status
Type
Placebo
Accepting
Trial Timing
Ended 2 years ago
What is this trial about?
What are the participation requirements?
Inclusion Criteria
- Patients submitted to cataract surgery with phacoemulsification with bilateral implantation of Asqelio Trifocal Toric IOL to avoid residual astigmatism
- Patient signing informed consent
- Clear intraocular media, except for cataracts in both eyes prior to surgery
- Monocular potential postoperative visual acuity of 20/25 or better
Exclusion Criteria
- Corneal astigmatism lower than 0.75D
- Patients who do not provide informed consent
- Patients who do not understand the study procedure
- Previous corneal surgery or trauma
- Irregular cornea (e.g. keratoconus)
- Choroidal hemorrhage
- Microphtalmos
- Severe corneal dystrophy
- Uncontrolled or medically controlled glaucoma
- Clinically significant macular changes
- Concomitant severe eye disease
- Non-age-related cataract
- Severe optic nerve atrophy
- Diabetic retinopathy
- Proliferative diabetic retinopathy
- Amblyopia
- Extremely shallow anterior camera
- Severe chronic uveítis
- Pregnant or nursing
- Rubella
- Mature/dense cataract that makes it difficult to examine the fundus preoperatively.
- Previous retinal detachment
- Concurrent participation in other research with drugs or clinical devices
- Expect to require another eye surgery during the study period